RT Journal
A1 Bernatsky S, Clarke A, Ramsey-Goldman R
T1 RIsk of lymphoma in autoimmune rheumatic conditions
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2006
FD June 12
VO 166
IS 11
SP 1233
OP 1234
DO 10.1001/archinte.166.11.1233-b
UL http://dx.doi.org/10.1001/archinte.166.11.1233-b
AB
We read with great interest the work of Zintzaras et al1 in their secondary analyses of cancer outcome in autoimmune rheumatic conditions including systemic lupus erythematous (SLE). Recently, the Systemic Lupus International Collaborating Clinics, in conjunction with the Canadian Network of Improved Outcomes in Systemic Lupus, published an international cohort study of cancer in SLE with 23 centers, with a total sample size of 9547 (an unprecedented number for epidemiologic research in SLE). For all cancers combined, the standardized incidence ratio estimate was 1.15 (95% confidence interval [CI], 1.05-1.27); for all hematologic malignancies, it was 2.75 (95% CI, 2.13-3.49); and for non-Hodgkin lymphoma (NHL), it was 3.64 (95% CI, 2.63-4.93). This thus provides, we believe, the most precise estimates generated to date for NHL occurrence in SLE.2